SHANGHAI and RALEIGH, N.C., July 16, 2013 -- WuXiPRA, a contract research organization (CRO) that offers Phase I-IV clinical trial services in China, Hong Kong, and Macau, today announced that James Pusey, M.D., has joined WuXiPRA as president and general manager. Dr. Pusey has more than 25 years of experience in medicine, international clinical trial management, CRO services, and global pharmaceutical sales, marketing, and clinical operations.
Prior to joining WuXiPRA, Dr. Pusey was founding CEO of Theorem Clinical Research, where he served as president and chief executive officer, executive chairman, and board director from 2009 through 2013. Previously, Dr. Pusey served as senior vice president and general manager of global clinical development at MDS Pharma Services. During his tenure at both of these global CROs, he successfully reorganized and developed their Asian businesses for significant growth.
Dr. Pusey has also served as president and chief executive officer of Orthologic, Inc., a biotechnology company based inPhoenix, Arizona; as executive vice president of the Pfizer/Serono joint venture on multiple sclerosis; and in a variety of roles at AstraZeneca and SmithKline Beecham. Before his business career, Dr. Pusey was a practicing physician at Royal Free Hospital, King George Hospital, St. Bartholomew's Hospital, and the Whittington Hospital, all based in London.
"We are pleased that Dr. Pusey has joined the company," said Colin Shannon, president and CEO, PRA. "His global experience in the CRO market will be an asset to WuXiPRA. With clinical trials continuing to expand in China, having Dr. Pusey onboard will allow us to establish a stronghold in the region."
"Under James's leadership, we believe WuXiPRA will become the clinical CRO of choice in China," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "WuXi PharmaTech's local expertise and PRA's leading-edge global systems and processes will enable customers to conduct the highest-quality clinical trials in China quickly and successfully for Chinese and international regulatory filings."
WuXiPRA Clinical Research (Shanghai) Co., Ltd. was formed in 2013 to provide clinical services in China for all PRA and WuXi clients around the globe. WuXiPRA has access to several thousand registered clinical trial sites in China and is focused on providing high-quality regulatory and operational services for those sites. WuxiPRA has offices in Beijing, Shanghai, Wuhan,Hong Kong, and Guangzhou and access to significant resources at both WuXi and PRA to provide customers with high-quality data and regulatory submissions.
About WuXi PharmaTech
As a research-driven and customer-focused company, WuXi PharmaTech (Cayman) Inc. provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi AppTec is the name for the operating subsidiaries of WuXi PharmaTech. For more information, please visit:http://www.wuxiapptec.com .
PRA serves our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world. To learn more about PRA, please visit http://www.praintl.com .
Cautionary Note Regarding Forward-Looking Statements for WuXi PharmaTech
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead are predictions about future events. Examples of forward-looking statements in this press release include statements about growth in clinical trials in China and the ability of WuXiPRA to provide highest-quality clinical trial services for the Chinese market. Although WuXi PharmaTech believes that the predictions are reasonable, future events are inherently uncertain, and the forward-looking statements may turn out to be incorrect. The forward-looking statements are subject to risks relating to, among other things, the possibility that WuXiPRA may experience operational difficulties and may fail to capitalize on the opportunities presented. Additional information about these and other relevant risks can be found in WuXi PharmaTech's Annual Report on Form 20-F for the year ended December 31, 2012. The forward-looking statements in this press release speak only as of the date on which they are made, and WuXi PharmaTech assumes no obligation to update any forward-looking statements except as required by law.